Degron Therapeutics
About
Degron Therapeutics develops novel molecular glue degrader (MGD) drugs using its proprietary GlueXplorer® platform to target historically intractable disease targets. This platform leverages a large, structurally differentiated compound library and advanced screening systems to address the challenges of rational MGD design. The company aims to "drug the undruggable" by creating new therapeutic options for diseases.
Key facts
At-a-glance profile data
- Website
- degrontx.com
- Headquarters
- San Diego, California, USA
- Founded
- 2020
- Employees
- 24
- Total funding
- $40M (Series A Extension)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 14 May 2026 | Series A Extension | $40M | LAPAM CAPITAL |
Add first review
Frequently asked
How much funding has Degron Therapeutics raised?
Degron Therapeutics has raised a total of $40M in funding. The most recent round on record is Series A Extension.
How many employees does Degron Therapeutics have?
Degron Therapeutics has approximately 24 people on record.